Jacek J Sznurkowski
Overview
Explore the profile of Jacek J Sznurkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sznurkowski J, Bodnar L, Szylberg L, Zolciak-Siwinska A, Danska-Bidzinska A, Klasa-Mazurkiewicz D, et al.
J Clin Med
. 2024 Aug;
13(15).
PMID: 39124620
: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well...
2.
Sznurkowski J, Rys J, Kowalik A, Zolciak-Siwinska A, Bodnar L, Chudecka-Glaz A, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836017
Background: Due to the increasing amount of published data suggesting that endometrial carcinoma is a heterogenic entity with possible different treatment sequences and post-treatment follow-up, the Polish Society of Gynecological...
3.
Sznurkowski J, Zawrocki A, Krawczynska N, Bienkowski M, Wasag B, Biernat W
Medicina (Kaunas)
. 2022 May;
58(5).
PMID: 35630004
: It has been demonstrated that Egfl7 promotes tumor cell escape from immunity by downregulating the activation of tumor blood vessels. : to analyze mRNA expression of within the tumor...
4.
Sznurkowski J, Zawrocki A, Sznurkowska K, Peksa R, Biernat W
Oncotarget
. 2017 Nov;
8(52):89903-89912.
PMID: 29163797
Background: Anti-immune programmed death-ligand 1 (PD-L1) pathway is used by the tumor to overcome immune system and serves as immunotherapy target in various malignancies. Aim: To investigate the expression of...
5.
Sznurkowski J, Zawrocki A, Biernat W
Oncotarget
. 2017 May;
8(28):46204-46210.
PMID: 28515351
Background: The p16Ink4a is not a surrogate marker for high-risk human papilloma virus (HPV) genotypes but indicates better prognosis in vulvar squamous cell carcinoma patients. Our recent study confirmed substantial...
6.
Sznurkowski J, Zawrocki A, Biernat W
BMC Cancer
. 2016 Jul;
16:465.
PMID: 27411473
Background: We aimed to evaluate the correlation between p16(ink4a)-overexpression and high risk (hr)HPV-DNA in vulvar squamous cell carcinoma (vSCC) tumors as well as the impact of both biomarkers on the...
7.
8.
Sznurkowski J, Milczek T, Emerich J
Arch Gynecol Obstet
. 2012 Dec;
287(6):1211-8.
PMID: 23263173
Objective: In 2009, International Federation of Gynecology and Obstetrics (FIGO) modified staging of vulvar cancer-the prognostic significance of the new classification relative to the prior system as well as to...
9.
Tabbaa Z, Gonzalez J, Sznurkowski J, Weaver A, Mariani A, Cliby W
Gynecol Oncol
. 2012 Jun;
127(1):147-52.
PMID: 22704951
Objective: In 2009, FIGO modified staging of vulvar cancer--the performance of the new classification relative to the prior system has not been assessed. We sought to investigate the impact of...
10.